Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and ...

The Schmidt Family Foundation has recently purchased the Mar y Cel property, a historic 350-acre estate located in the scenic ...

Citizens upgraded Allogene Therapeutics (NASDAQ:ALLO) to Market Perform from Market Underperform on Friday, establishing a $5 ...

Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval.

VIENNA, Va., February 20, 2025--CEL-SCI to initiate Multikine Confirmatory Phase 3 Cancer Trial. VIENNA, Va., February 18, 2025--CEL-SCI reports fiscal Q1 2025 financial results: Multikine shows ...

--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced it is in the final stages for the launch of its 212-patient Confirmatory Registration Study for Multikine* (Leukocyte ...

Allogene Therapeutics reports promising results for cema-cel, an allogeneic CAR T therapy for relapsed/refractory large B-cell lymphoma. Allogene Therapeutics has published promising results from ...

Season 3 gears up for an action-packed fifth week, featuring four intense matches this weekend at the Cebu Institute of ...